Tag - 23andMe

From Experimentation to Execution: How 2025 Reset the Trajectory of Healthcare and What 2026 Will Demand

23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process

Dozens of states sue to block the sale of 23andMe personal genetic data without customer consent

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness

2024 in Review

2021 – Precision Medicine linked with Genomic Medicine: A Work in Progress

Enabling Precision Medicine: Life (Sciences) in 2030

23andMe to Merge with Virgin Group’s VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and Therapeutic Development through Human Genetics

2020 Was Not Just About COVID-19

2019 in Review – Major Acquisitions, Population Studies, Gigantic Founding Rounds, Technological Advancements, and ….

2018: Population Studies, Immunotherapy, CRISPR, Genomic Medicine,…2019

This year’s Bio-IT 2016 With Clinical Genetics as the Frontrunner

At AGBT 2016, the Winners Are Long Reads and Whole Solutions

The JP Morgan Healthcare Conference from Afar

2015 – A Year of Health Initiatives, Commercial Milestones, Company Acquisitions, and Scientific Achievements

Copyright © 2026. enlighenbio LLC. All rights reserved.